Annexin Pharmaceuticals AB (publ) (STO:ANNX)
Sweden · Delayed Price · Currency is SEK 12.85
-0.10 (-0.77%)
Jun 11, 2026, 5:03 PM CET
Annexin Pharmaceuticals AB Earnings Call Transcripts
Fiscal Year 2025
-
A novel protein therapy for retinal vein occlusion and diabetic retinopathy shows rapid, durable effects and could significantly reduce the need for costly anti-VEGF injections. Phase 2A results have impressed US key opinion leaders, and a phase 2B trial is planned, with the US market as the initial focus.